USA flag logo/image

An Official Website of the United States Government

Studies in Mice to Improve Efficacy/Safety of Paclitaxel/Docetaxel with an…

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
95911
Program Year/Program:
2010 / SBIR
Agency Tracking Number:
CA150448
Solicitation Year:
N/A
Solicitation Topic Code:
NCI
Solicitation Number:
N/A
Small Business Information
ANGIOGENEX
425 MADISON AVE NEW YORK, NY 10017-1110
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2010
Title: Studies in Mice to Improve Efficacy/Safety of Paclitaxel/Docetaxel with an Anti-I
Agency: HHS
Contract: 1R43CA150448-01
Award Amount: $163,150.00
 

Abstract:

DESCRIPTION (provided by applicant): Inhibitor of differentiation (Id) genes and proteins play a significant role in tumor biology, and an anti-Id therapy in combination with a taxanes, a widely prescribed class of cytotoxic (paclitaxel/docetaxel, docetaxe l or protein-bound paclitaxel) to treat cancer, is hypothesized to significantly improve the efficacy of the taxane without compromising safety while also providing additional anti-cancer activity. An effective Id1 inhibitor would potentially improve the e fficacy of the taxanes by three distinct mechanisms: (i) preventing endothelial repair and thereby promoting the intrinsic anti-angiogenic effect of paclitaxel/docetaxel, (ii) lowering the anti-apoptotic environment of the tumor making it more susceptible to the cytotoxicity of paclitaxel/docetaxel and (iii) augmenting the cytotoxicity of paclitaxel/docetaxel by a direct anti-cancer effect. The goal of this proposal is to provide data to justify formal preclinical development and initial clinical evaluation of this therapeutic approach with an anti-Id1 small molecule. Experiments to be funded by the grant include xenograft studies in mice to establish the optimum dosing regimen for both the anti-Id agent and the taxanes. PUBLIC HEALTH RELEVANCE: Anti- microtubule taxanes like paclitaxel and docetaxel are widely prescribed cytotoxics to treat cancer. An effective Id1 inhibitor would potentially improve the efficacy of taxanes by three distinct mechanisms: (i) preventing endothelial repair and thereby pro moting the intrinsic anti-angiogenic effect of taxanes, (ii) lowering the anti-apoptotic environment of the tumor making it more susceptible to the cytotoxicity of the taxanes, and (iii) augmenting the cytotoxicity of the taxanes by a direct anti-cancer ef fect. The goal of this proposal is to provide data to justify formal preclinical development and initial clinical evaluation of this therapeutic approach using an anti-Id1 small molecule.

Principal Investigator:

William A. Garland
8314266808
BGARLAND@COMPUSERVE.COM

Business Contact:


garlandw@angiogenex.com
Small Business Information at Submission:

ANGIOGENEX
ANGIOGENEX 425 MADISON AVE NEW YORK, NY 10017

EIN/Tax ID: 113412407
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No